Overview / Abstract: |
Target Audience Program Overview Join an expert panel of ENTs to explore the underlying pathways that lead to NPs and drive recurrent disease and treatment resistance. Panelists will also discuss the burdens faced by patients with NPs and evidence supporting the efficacy and safety of biologic agents for the treatment of refractory and recurrent NPs. Do you have patients with NPs who could benefit from education on biologic treatment options? Direct your patients to MedLive.com to access the activity, “Making Your Voice Heard: Could Your Nasal Polyps Benefit from a Biologic Medicine?” Learning Objectives Describe the inflammatory relationships between NPs and common T2-driven comorbidities |
Expiration |
Oct 12, 2024 |
Discipline(s) |
Physician CME |
Format |
Online |
Credits / Hours |
1.0 AMA PRA Category 1 Credit™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Faculty Noam Cohen, MD, PhD |
Sponsors / Supporters / Grant Providers |
Regeneron Pharmaceuticals, Inc. and and Sanofi. |
Keywords / Search Terms |
Relias LLC Relias LLC., FreeCME., Respiratory Free CE CME |